This meta-analysis demonstrated that BTKi monotherapy has superior outcomes compared to the combination therapy and has a manageable safety profile in patients with untreated or relapsed/refractory CLL and SLL. Here, IBTK is linked to B-cell chronic lymphocytic leukemia.